Why the study?
Does pharmacological inhibition of the Renin Angiotensin System with enalapril, candesartan, or aliskiren alter urinary cytokine profiles in a rat model of chronic kidney disease?
Does pharmacological inhibition of the Renin Angiotensin System with enalapril, candesartan, or aliskiren alter urinary cytokine profiles in a rat model of chronic kidney disease?
Different sites of renin-angiotensin system blockade trigger differential cytokine responses in a rat model of chronic kidney disease, despite similar improvements in renal function and blood pressure.
Answers are grounded in this paper and cite their sources.
Similar IL-6 reductions across RAS inhibitors in rat CKD; leaves open differential cytokine effects and human translation.
INTRODUCTION: It is still unknown how the pharmacological inhibition of the Renin Angiotensin System (RAS) impacts the levels of inflammation and fibrosis biomarkers. OBJECTIVE: This study sought to evaluate the effect of enalapril, candesartan and aliskiren on urinary levels of cytokines in a model of chronic kidney disease (CKD). METHODS: Male Wistar rats were submitted to surgical removal of ¾ of renal parenchyma to induce CKD (¾ nephrectomy), or subjected to sham surgery (control). Animals were then randomized into five groups: Sham surgery receiving vehicle; ¾ Nephrectomy receiving vehicle; ¾ Nephrectomy receiving enalapril (10 mg/kg); ¾ Nephrectomy receiving candesartan (10 mg/kg) and ¾ Nephrectomy receiving aliskiren (10 mg/kg). Urine output, water intake, mean arterial pressure (MAP) and urinary concentrations of creatinine, urea, albuminuria, Na+, K+, interleukin (IL) -1β, IL-6, IL-10 and transforming growth factor beta (TGF-β) were measured. RESULTS: Nephrectomy significantly impaired renal function, increased MAP and altered the levels of all evaluated cytokines in urine. Enalapril, candesartan and aliskiren improved renal function and decreased MAP and IL-6 when compared to vehicle-treated nephrectomized group. Candesartan and aliskiren decreased IL-1β, while only candesartan reduced TGF-β and only aliskiren increased IL-10. CONCLUSION: Enalapril, candesartan and aliskiren presented similar effects on improving renal function and reducing MAP and urinary levels of IL-6 in rats with CKD. On the other hand, cytokine profile differed according to the treatment, suggesting that differential mechanisms were triggered in response to the site of RAS blockade.
No takes yet. Share an insight, caveat, or question.
Baracho et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: